ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 1171 • 2015 ACR/ARHP Annual Meeting

    Plasma Soluble ST2 Levels Are Independently Associated with Both Carotid Atherosclerosis and Compromised Cortical Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis

    Jiayun Shen1, Qing Shang1, Edmund Li1, Tracy Y. Zhu2, Ling Qin2 and Lai-Shan Tam1, 1Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, 2Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China

    Background/Purpose: Patients with PsA have both increased risk of subclinical atherosclerosis and lower cortical volumetric BMD (vBMD) compared with the general population, probably as a…
  • Abstract Number: 1677 • 2015 ACR/ARHP Annual Meeting

    Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis

    Mathijs G.A. Broeren1, Miranda B. Bennink1, Onno J. Arntz2, Wim van den Berg2 and Fons A.J. van de Loo2, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, The Netherlands, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: The current treatment for patients with rheumatoid arthritis (RA) consists of biological drugs, often in combination with methotrexate. However, some patients fail to respond…
  • Abstract Number: 1920 • 2015 ACR/ARHP Annual Meeting

    Differential Production of Th17-Related Cytokines By Toll like Receptor (TLR)-Ligands-Stimulated Monocyte-Derived Dendritic Cells (Mo-DCs) from Systemic Sclerosis (SSc) Patients; Relevance of IL-22 and IL-33 According to Disease Subtype and Stage

    Tatiana Sofia Rodriguez-Reyna1, Adrián Caballero1, Luís Jiménez-Álvarez2, Gustavo Ramirez2, José Eduardo Márquez García2, Alfredo Cruz Lagunas3, Guadualupe Lima4, Janette Furuzawa-Carballeda5, Luis Llorente1 and Joaquin Zuniga6, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 3Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 6Immunology, Instituo Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico, Mexico

    Background/Purpose: Systemic sclerosis (SSc) patients exhibit alterations in innate and acquired cellular responses including an enhanced inflammatory response to toll like receptor (TLR) agonists that…
  • Abstract Number: 1922 • 2015 ACR/ARHP Annual Meeting

    Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis

    Nicolas Dumoitier1,2,3,4, Sebastien Lofek2,3,5, Alexis Regent6, Jonathan London7, Benjamin Chaigne1,2,3,8, Benjamin Terrier2,7,9,10, Nadine Varin-Blank4,11 and Luc Mouthon1,2,4,6, 1Infection, Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, 2CNRS, UMR8104, Paris, France, 3Université Paris Descartes, Paris, France, 4Labex Inflamex, Université Sorbonne Paris Cité, Paris, France, 5Infection,Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, 6Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 7Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 8Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochinl, Paris, France, 9Infection, Immunité, Inflammation, Institut Cochin INSERM U1016, Paris, France, 10Université Paris Descartes, paris, France, 11UFR SMBH, INSERM, UMR978, Bobigny, France

    Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by fibroblasts activation, increased extra-cellular matrix synthesis associated with autoimmunity. However, the potential role…
  • Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting

    Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

    Alice B. Gottlieb1, Philip J. Mease2, Raquel S. Cuchacovich3,4, Catherine L. Shuler5, Chen-Yen Lin5, Russel T. Burge5, Suvajit Samanta5, Chin H. Lee5 and Dafna D. Gladman6, 1Dermatology, Tufts Medical Center, Boston, MA, 2Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, 3School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, 4Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Indianapolis, IN, 6Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
  • Abstract Number: 2876 • 2014 ACR/ARHP Annual Meeting

    Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers,…
  • Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of NNC0114­0006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis

    Juan D. Cañete1, Piotr Leszczynski2, Rikke Riisbro3 and Klaus S. Frederiksen3, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, 3Novo Nordisk A/S, Søborg, Denmark

    Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…
  • Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting

    Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh1, Sharayah Riegsecker2, Sadiq Umar1 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 2Department of Pharmacology, University of Toledo, Toledo, OH

    Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
  • Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

    Jing He1, Xia Zhang2, Xiaolin Sun3, Jianping Guo3, Yunbo Wei4, Zhaohua Hou4, Yu Di5 and Zhanguo Li3, 1Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, 3Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 4Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, 5Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria

    Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
  • Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting

    Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE

    Jens Y. Humrich1, Caroline von Spee-Mayer1, Elise Siegert1, Angelika Rose1, Tobias Alexander2, Falk Hiepe1, Andreas Radbruch3, Gerd Burmester4 and Gabriela Riemekasten1, 1Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 4Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

    Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
  • Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting

    Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis

    Anderson Gaweco1,2, Samantha Palmer1, Rambon Shamilov1, Caroline Stremnitzer1, Katie Matthews1, Michael Fisher1, William Windsor1, James Blinn1, Ellen M. Ginzler3 and Jefferson Tilley1, 1Innovimmune Biotherapeutics, Brooklyn, NY, 2SUNY-Downstate Medical Center, Brooklyn, NY, 3Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY

    Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
  • Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting

    Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
  • Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting

    Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome

    Loredana Cifaldi1, Giusi Prencipe2, Ivan Caiello2, Claudia Bracaglia2, Raffaele Strippoli3 and Fabrizio De Benedetti Sr.2, 1Paediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3Cellular Biotechnologies and Haematology, Sapienza Rome University, Rome, Italy

    Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…
  • Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting

    Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects

    Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL

    Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
  • Abstract Number: 81 • 2014 ACR/ARHP Annual Meeting

    Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts

    Mukundan Attur1, Alexander Statnikov2, Svetlana Krasnokutsky Samuels1, Virginia B. Kraus3, Joanne Jordan4, Braxton D. Mitchell5, Michelle Yau6, Jyoti Patel1, Constantin F. Aliferis2, Marc C. Hochberg7, Jonathan Samuels1 and Steven B. Abramson8, 1Rheumatology, NYU Langone Medical Center, New York, NY, 2Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, 3Medicine/Rheumatology, Duke University Medical Center, Durham, NC, 4Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, 6Epidemiology and Public Health, University of Maryland, Baltimore,, MD, 7Medicine, University of Maryland School of Medicine, Baltimore, MD, 8Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY

    Background/Purpose: We and others have demonstrated low grade inflammation exists in OA joint tissues, where it may contribute to disease pathogenesis. In the current studies…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology